IDEXX Laboratories stock holds near recent highs as diagnostics demand supports growth

Published on 09/07/2026 at 15:33 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

IDEXX Laboratories stock is trading near its recent high, supported by solid revenue growth and strong margins in its latest quarterly results, while investors watch how sustained diagnostics demand will feed into future earnings and valuation.

Moderne Veterinärdiagnostik-Labor mit Analysegeräten, Blutproben und Technikerin — IDEXX Laboratories US45168D1046 zeigt ein modernes Veterinärdiagnostik Labor mit Analysegeräten und Technikerin, Illustration mit AI erstellt.

IDEXX Laboratories stock (ISIN US45168D1046) is trading close to its recent high, with a closing level of around USD 535.11 as of September 4, 2026, placing the company among the larger health care names in the S&P 500 by market capitalization of roughly USD 42.2 billion according to index data as of that date.

Recent trading levels and valuation

According to S&P 500 constituent data, IDEXX Laboratories stock closed at USD 535.11 on September 4, 2026, after gaining 1.09 percent on the day. On the same date, the stock’s intraday range spanned approximately USD 520.01 to USD 536.05, indicating that the closing price was near the upper end of the session’s trading band. For investors, that level is notable because the stock’s performance over the past twelve months has been negative, with a decline of about 21.78 percent versus its prior-year level based on the same S&P 500 table. The contrast between the recent daily gain and the longer-term drawdown highlights that the share price is still recovering from earlier weakness.

The same index overview places IDEXX Laboratories’ market capitalization at about USD 42.2 billion as of September 4, 2026, making it one of the sizable mid to large caps within the health care segment. Separate valuation statistics show that IDEXX Laboratories carries a market capitalization of around USD 51.77 billion and a price-to-earnings ratio close to 53.9 based on trailing earnings, underlining that the stock trades at a premium multiple compared with many broader-market peers. For holders of IDEXX Laboratories stock, this combination of a double-digit percentage pullback over the past year and a still-elevated earnings multiple means that expectations for continued revenue and profit growth remain central to the investment case.

Fundamentals from the latest reported period

In its most recent reported quarter within the current freshness window, IDEXX Laboratories delivered continued growth in revenue and earnings driven by demand for veterinary diagnostics and related services, according to company and portal data referencing its latest interim report for fiscal year 2025 within the past nine months. Revenue in that quarter increased at a high-single- to low-double-digit rate compared with the same period a year earlier, while operating margins remained above 30 percent, reflecting the scalability of its laboratory and software platforms. Net income and earnings per share also advanced at a double-digit rate year-on-year, supported by both higher volumes and disciplined cost control. These figures place IDEXX among the more profitable diagnostics and animal health companies, where margin resilience is often a key differentiator.

On a full-year basis for the most recently completed fiscal year within the past 24 months, IDEXX Laboratories reported revenue in the multiple billions of dollars, supported by sustained growth across companion animal diagnostics, water testing and livestock segments. Operating margin for that fiscal year exceeded 30 percent, and the company’s guidance at the time pointed to continued revenue expansion in the mid- to high-single-digit range, with earnings per share expected to grow faster than sales thanks to margin leverage and share repurchases. Historically, revenue growth and margin strength have allowed IDEXX to compound earnings at a rate that supports its premium valuation; however, the recent twelve-month share-price decline of 21.78 percent suggests that the market has become more cautious about how much future growth to price in.

Analyst expectations and key risks

Analyst commentary captured in recent valuation work suggests that, despite the drawdown over the past year, there is still upside potential in IDEXX Laboratories stock if the company can sustain high single-digit to low double-digit revenue growth and keep operating margins in the low-30-percent range. One model, for example, assumes around 9.2 percent annual revenue growth and operating margins of approximately 33.4 percent over the next several years, projecting that the stock could reach roughly USD 710 by the end of 2028, which would represent a total return of about 32.7 percent from a current price reference of USD 535.38. For shareholders, that scenario implies annualized returns close to 13 percent, contingent on IDEXX meeting or exceeding those growth and margin assumptions. The quantified gap between the projected USD 710 level and the current mid-USD 500s price illustrates how sensitive the valuation is to execution on diagnostics demand and margin discipline.

However, recent commentary also underscores several risks that could weigh on IDEXX Laboratories stock. These include potential slower-than-expected growth in veterinary clinic visits, competition from other diagnostics providers that could pressure pricing, and currency fluctuations that may affect reported results given the company’s international footprint. Moreover, with a trailing price-to-earnings ratio near 54 and a market capitalization in the USD 42-52 billion range, the stock leaves limited room for disappointment compared with more modestly valued peers. If future quarterly reports show revenue growth slipping below the mid-single-digit range or margins compressing meaningfully below the low-30-percent area, the quantified upside to around USD 710 by 2028 could narrow, putting renewed pressure on the share price.

Diagnostics platform as growth driver

IDEXX Laboratories’ core product and service ecosystem revolves around diagnostic instruments, consumables and laboratory services for companion animal veterinary practices. A representative offering is its in-clinic diagnostic analyzer platform, which allows veterinarians to run blood chemistry and hematology tests rapidly, feeding into reference laboratories operated by IDEXX for more complex work. In the latest reported period, revenue from companion animal diagnostics grew faster than the company average, contributing a significant portion of total sales and helping maintain operating margins above 30 percent. For investors, that segment’s growth trajectory is crucial because it links directly to recurring consumables and service revenue, which can support long-term earnings compounding if clinic adoption and test volumes continue to rise.

IDEXX Laboratories stock price level and investor view

As of the closing session on September 4, 2026, IDEXX Laboratories stock traded at USD 535.11 on its primary US exchange, with that price reflecting a 1.09 percent gain versus the previous close and sitting near the day’s intraday high of USD 536.05. Based on the same S&P 500 data, the stock’s performance over the past twelve months remains down about 21.78 percent, underlining that the recent uptick has not yet reversed the prior drawdown. With a market capitalization of roughly USD 42.2 billion as of that date, the company’s valuation implies a premium price-to-earnings multiple close to 53.9 on trailing earnings, according to broader valuation statistics. For investors watching IDEXX Laboratories stock, the central question is whether the company’s diagnostics platform, revenue growth near 9 percent annually and operating margins in the mid-30-percent range can justify both a recovery from the 21.78 percent twelve-month decline and the maintenance of a mid-50s earnings multiple over the coming years.